MET and pancreatic neoplasm: We used four small-molecule TKIs (BMS777607, PHA665752, INCB28060, Tivantinib) to explore the function of RON and MET in pancreatic cancer cells and whether RON and MET could serve as new targets for future treatment of pancreatic cancer.